KAWASAKI DISEASE IN KAZAKHSTAN: AN UNMET CLINICAL AND PUBLIC HEALTH ISSUE?

Keywords: Kawasaki disease, Mucocutaneous lymph node syndrome, Coronary aneurysm, Intravenous immunoglobulin, Kazakhstan, Central Asia, Hypothesis

Abstract

Kawasaki disease (KD) is a systemic vasculitis targeting medium-sized and small arteries. It manifests in young children. If not appropriately treated, KD leads to the development of coronary artery aneurysms inabout 20% of patients. No local evidence-based clinical and epidemiological data on KD are currently available in Kazakhstan. The awareness of KD among physicians is inadequate, resulting in underdiagnosis of the disease in the country. Given the high priority of cardiovascular morbidity and mortality in Central Asian countries, clinical and epidemiological studies on KD along with measures for early diagnosis and management of the patients with cardiovascular affections are warranted.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Sundel RP. Kawasaki Disease. Rheum Dis Clin North Am 2015;41(1):63–73.

Son MB, Sundel RP. Kawasaki Disease. In: Textbook of Pediatric Rheumatology. 7th ed., Elsevier, Philadelphia, 2016:467–482.

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation 2017;135(17):e927–e999.

Poddighe D. Complete Kawasaki disease (KD) with peculiar skin manifestations. BMJ Case Rep 2017;2017:pii: bcr-2017-222724.

Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr 2018;44(1):102.

Burns JC, Hoshino S, Kobayashi T. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria. Lancet Child Adolesc Health 2018;2(12):840–841.

Available from: http://www.rcrz.kz/index.php/ru/2017-03-12-10-51-13/klinicheskie-protokoly [Accessed Oct 5, 2019].

Rodó X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep 2011;1:152.

Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22(2):79–85.

Lyskina G, Bockeria O, Shirinsky O, Torbyak A, Leontieva A, Gagarina N, et al. Cardiovascular outcomes following Kawasaki disease in Moscow, Russia: A single center experience. Glob Cardiol Sci Pract 2017;2017(3):e201723.

Rodó X, Curcoll R, Robinson M, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A 2014;111(22):7952–7957.

Nakamura Y, Aso E, Yashiro M, et al. Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009. J Epidemiol 2013;23:429–434.

Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults withsuspected myocardial ischemia. Circulation 2012;125:2447–2453.

Aringazina A, Kuandikov T, Arkhipov V. Burden of the Cardiovascular Diseases in Central Asia. Cent Asian J Glob Health 2018;7(1):321.

WHO: Country statistics and global health estimates by WHO and UN partners. Kazakhstan: WHO statistical profile. Available from: https://www.who.int/gho/countries/kaz.pdf [Accessed Oct 5, 2019].

Semenova Y. Evaluation of screening programs for cardiovascular diseases in East Kazakhstan. Eur J Public Health 2018;28(Suppl. 4):397–398.

Data Presentation System Kazakhstan. From Medinform website. Available from: http://dps.medinfo.kz [Accessed Oct 5, 2019].

Published
2020-08-07